EGFR and non-small cell lung carcinoma: This has important therapeutic implications for other oncogene driven NSCLCs as MET amplification and HGF expression are common mechanisms of de novo and acquired resistance to TKIs in NSCLC [7, 40], including to the third generation EGFR TKI osimertinib (15–22%) [50, 51].